Prospective observational study of castration-resistant prostate cancer with homologous recombination repair-related gene mutations.

Not Applicable

Recruiting

• Conditions: prostate cancer; D011471

• Registration Number: JPRN-jRCT1050230026
• Lead Sponsor: Goto Takayuki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-23
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 400

Inclusion Criteria

1) Patients with castration-resistant prostate cancer who have mutations in any of the following homologous recombination repair-related genes as a result of germline analysis (BRACAnalysis) or cancer panel testing with all of the following HRR-related 15 genes as targets, and who have agreed to a prospective observational study
Homologous recombination repair gene mutations of interest: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L
2) Patients who have agreed to undergo genetic analysis of their blood before starting treatment and at the time of acquisition of resistance to treatment when using PARP inhibitors or platinum drugs or immune checkpoint inhibitors during prospective observational studies
3) Those who were 20 years of age or older at the time of obtaining consent

Exclusion Criteria

1) Patients for whom routine follow-up, including imaging, is not possible due to comorbidities or other reasons
2) Other patients deemed unsuitable by the principal investigator or sub-investigator to conduct the study

Study & Design

• Study Type: Observational
• Study Design: Not specified